ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016
Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04533555 (Randomized Trial of Universal vs. Guideline-directed Germline Testing Among Young Adults With Cancer), which is not on this map. Cited by 119 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial of Universal vs. Guideline-directed Germline Testing Among Young Adults With Cancer
Who cites it
119 citing papers in PubMed, 2 syntheses or guidelines pooled it, 178 citations in OpenAlex.
- Machine learning models in predicting graft survival in kidney transplantation: meta-analysis.BJS open · 2023Pooled it
- Diversity in Machine Learning: A Systematic Review of Text-Based Diagnostic Applications.Applied clinical informatics · 2022Pooled it
- Randomized control trial comparing genetic counseling service delivery models in an underserved population.Journal of genetic counseling · 2025Trial
- Social vulnerability and genetic service utilization among unaffected BRIDGE trial patients with inherited cancer susceptibility.BMC cancer · 2025Trial
- Randomized trial promoting cancer genetic risk assessment when genetic counseling cost removed: 1-year follow-up.JNCI cancer spectrum · 2024Trial
- Identifying Mediators of Intervention Effects Within a Randomized Controlled Trial to Motivate Cancer Genetic Risk Assessment Among Breast and Ovarian Cancer Survivors.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2023Trial
- Pilot study of a culturally sensitive intervention to promote genetic counseling for breast cancer risk.BMC health services research · 2022Trial
- Cancer Health Assessments Reaching Many (CHARM): A clinical trial assessing a multimodal cancer genetics services delivery program and its impact on diverse populations.Contemporary clinical trials · 2021Trial
- Comparing models of delivery for cancer genetics services among patients receiving primary care who meet criteria for genetic evaluation in two healthcare systems: BRIDGE randomized controlled trial.BMC health services research · 2021Trial
- Disparities in genetic services utilization in a random sample of young breast cancer survivors.Genetics in medicine : official journal of the American College of Medical Genetics · 2019Trial
- Medical oncologists' willingness to participate in bundled payment programs.BMC health services research · 2018Trial
- Intervention Mediators in a Randomized Controlled Trial to Increase Colonoscopy Uptake Among Individuals at Increased Risk of Familial Colorectal Cancer.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2017Trial
- Knowledge, attitudes, and self-efficacy toward cancer genetic testing among Black women with and without breast cancer.Cancer causes & control : CCC · 2026Article
- Community-Driven Research Priorities for Genetic Counseling: Shaping the Future of Genetic Counseling Research by Centering Multicultural Perspectives.Journal of genetic counseling · 2026Article
- Differences in Cascade Genetic Testing Among Families With Hereditary Cancer Risk.JAMA network open · 2026Article
- Multigene Germline Testing in Patients with DCIS vs Invasive Breast Cancer in a Large, Integrated Health Care System.Annals of surgical oncology · 2026Article
- Biomarker, treatment patterns, and survival differences in metastatic triple-negative breast cancer by race in the United States.NPJ breast cancer · 2026Article
- Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study.JCO precision oncology · 2026Article
- Review
- BRCA testing utilization among commercially insured women with breast or ovarian cancer.Breast cancer research and treatment · 2025Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
purposeRacial disparities in BRCA1/2 testing have been documented, but causes of these disparities are poorly understood. The study objective was to investigate whether the distribution of black and white patients across cancer providers contributes to disparities in BRCA1/2 testing. PATIENTS AND
methodsWe conducted a population-based study of women in Pennsylvania and Florida who were 18 to 64 years old and diagnosed with invasive breast cancer between 2007 and 2009, linking cancer registry data, the American Medical Association Physician Masterfile, and patient and physician surveys. The study included 3,016 women (69% white, 31% black), 808 medical oncologists, and 732 surgeons.
resultsBlack women were less likely to undergo BRCA1/2 testing than white women (odds ratio [OR], 0.40; 95% CI, 0.34 to 0.48; P < .001). This difference was attenuated but not eliminated by adjustment for mutation risk, clinical factors, sociodemographic characteristics, and attitudes about testing (OR, 0.66; 95% CI, 0.53 to 0.81; P < .001). The care of black and white women was highly segregated across surgeons and oncologists (index of dissimilarity 64.1 and 61.9, respectively), but adjusting for clustering within physician or physician characteristics did not change the size of the testing disparity. Black women were less likely to report that they had received physician recommendation for BRCA1/2 testing even after adjusting for mutation risk (OR, 0.66; 95% CI, 0.54 to 0.82; P < .001). Adjusting for physician recommendation further attenuated the testing disparity (OR, 0.76; 95% CI, 0.57 to 1.02; P = .06).
conclusionAlthough black and white patients with breast cancer tend to see different surgeons and oncologists, this distribution does not contribute to disparities in BRCA1/2 testing. Instead, residual racial differences in testing after accounting for patient and physician characteristics are largely attributable to differences in physician recommendations. Efforts to address these disparities should focus on ensuring equity in testing recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.